Mafosfamide
From Wikipedia, the free encyclopedia
| Mafosfamide | |
|---|---|
 |
|
| IUPAC name | 2-{[2-[bis(2-chloroethyl)amino]-2-oxo- 1-oxa-3-aza-2λ5-phosphacyclohex- 4-yl}sulfanyl]ethanesulfonic acid |
| Identifiers | |
| CAS number | [88859-04-5] |
| PubChem | |
| MeSH | |
| SMILES | C1COP(=O)(NC1SCCS(=O)(=O)O)N(CCCl)CCCl |
| Properties | |
| Molecular formula | C9H19Cl2N2O5PS2 |
| Molar mass | 401.269 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references |
|
Mafosfamide (INN) is an oxazaphosphorine (cyclophosphamide-like) alkylating agent under investigation as a chemotherapeutic. Several Phase I trials have been completed.[1][2]
[edit] References
- ^ Intrathecal Mafosfamide. ClinicalTrials.gov. U.S. National Institutes of Health (August 21, 2006). Retrieved on 2007-07-13. ClinicalTrials.gov Identifier NCT00062881.
- ^ Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors. ClinicalTrials.gov. U.S. National Institutes of Health (February 20, 2007). Retrieved on 2007-07-13. ClinicalTrials.gov Identifier NCT00031928.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
